OSE Immunotherapeutics Stock
Stocks
OSE
FR0012127173
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
19:55:00 29/10/2026 +03
|
After hours 21:01:48 | |||
| 2.106 EUR | -3.84% |
|
2.206 | +4.75% |
| Market Cap | 51.51M 57.51M 47.52M 43M 80.41M 5.48B 81.71M 567M 226M 2.87B 216M 211M 9.08B | P/E 2026 * |
-1.68x | P/E 2027 * | -1.93x |
|---|---|---|---|---|---|
| Enterprise Value | 88.63M 98.95M 81.77M 74M 138M 9.42B 141M 976M 389M 4.93B 371M 363M 15.62B | EV / Sales 2026 * |
18.1x | EV / Sales 2027 * | 10.5x |
| Free-Float |
78.15% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| OSE | Real-time | |
CBOE
| OSEp | Real-time | |
|
Börse Stuttgart
| 6OP | Delayed | |
|
Tradegate
| 6OP | Real-time | |
|
Deutsche Boerse AG
| 6OP | Delayed | |
|
CBOE
| 0RAD | Real-time | |
|
Boerse Muenchen
| 6OP | Real-time |
Last Transcript: OSE Immunotherapeutics
| 1 day | -3.84% | ||
| 1 week | +3.13% | ||
| Current month | -5.98% | ||
| 1 month | -6.48% | ||
| 3 months | -34.56% | ||
| 6 months | -46.74% | ||
| Current year | -59.11% |
| 1 week | 1.98 |  | 2.33 |
| 1 month | 1.98 | | 2.33 |
| Current year | 1.98 | | 5.9 |
| 1 year | 1.98 | | 6.1 |
| 3 years | 1.98 | | 11.58 |
| 5 years | 1.98 | | 12.28 |
| 10 years | 1.98 | | 15.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Le Bozec
CEO | Chief Executive Officer | - | 30/09/2025 |
Thomas Gidoin
DFI | Director of Finance/CFO | 43 | 20/08/2025 |
Aurore Morello
CTO | Chief Tech/Sci/R&D Officer | - | 02/12/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Markus J. Cappel
CHM | Chairman | 65 | 30/09/2025 |
Jonathan Cool
BRD | Director/Board Member | 66 | 30/09/2025 |
Marc Le Bozec
BRD | Director/Board Member | - | 30/09/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 11/13/24 A | Sell | Director | 30,000 | 0.1375% | ||
| 11/12/24 A | Sell | Chief Administrative Officer | 10,000 | 0.0458% | ||
| 6/21/24 A | Exercice | Director | 10,000 | 0.0459% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.84% | +3.13% | -64.34% | -52.46% | 57.41M | |
| +0.34% | -3.03% | +37.45% | +61.06% | 64.14B | |
| +0.98% | +2.68% | +12.25% | +83.90% | 55.53B | |
| +1.75% | +2.01% | +13.30% | +105.71% | 53.03B | |
| -1.17% | -1.32% | +26.08% | +55.03% | 45.99B | |
| -0.91% | -3.18% | +17.55% | +98.33% | 42.45B | |
| -0.21% | +0.54% | +225.24% | +928.37% | 40.45B | |
| -0.26% | -4.20% | +10.86% | +45.18% | 32.25B | |
| -2.07% | +42.73% | +103.77% | +90.26% | 34.47B | |
| -2.72% | -8.79% | +22.58% | -5.63% | 24.23B | |
| Average | -0.86% | +4.02% | +40.47% | +140.98% | 39.26B | |
| Weighted average by Cap. | -0.26% | +3.13% | +49.19% | +160.13% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.9M 5.47M 4.52M 4.09M 7.65M 521M 7.77M 53.93M 21.52M 273M 20.53M 20.09M 864M | 10.53M 11.76M 9.71M 8.79M 16.44M 1.12B 16.7M 116M 46.24M 586M 44.12M 43.18M 1.86B |
| Net income | -30.59M -34.15M -28.22M -25.53M -47.75M -3.25B -48.52M -337M -134M -1.7B -128M -125M -5.39B | -21.47M -23.97M -19.8M -17.92M -33.51M -2.28B -34.05M -236M -94.26M -1.19B -89.94M -88.03M -3.78B |
| Net Debt | 37.12M 41.45M 34.25M 30.99M 57.96M 3.95B 58.89M 409M 163M 2.07B 156M 152M 6.54B | 59.25M 66.15M 54.66M 49.47M 92.5M 6.3B 93.99M 652M 260M 3.3B 248M 243M 10.44B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/10/26 | €2.106 | -3.84% | 167,230 |
| 28/10/26 | €2.190 | +3.11% | 534,530 |
| 27/10/26 | €2.124 | +3.21% | 145,682 |
| 26/10/26 | €2.058 | +2.69% | 115,812 |
| 23/10/26 | €2.004 | -1.86% | 106,689 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- OSE Stock
Select your edition
All financial news and data tailored to specific country editions
